Promise and Peril of Population Genomics for the Development of Genome-First Approaches in Mendelian Cardiovascular Disease
- 1 February 2021
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation: Genomic and Precision Medicine
- Vol. 14 (1), e002964
- https://doi.org/10.1161/circgen.120.002964
Abstract
The rich tradition of cardiovascular genomics has placed the field in prime position to extend our knowledge toward a genome-first approach to diagnosis and therapy. Population-scale genomic data has enabled exponential improvements in our ability to adjudicate variant pathogenicity based on allele rarity, and there has been a significant effort to employ these sizeable data in the investigation of rare disease. Certainly, population genomics data has great potential to aid the development of a genome-first approach to Mendelian cardiovascular disease, but its use in the clinical and investigative decision making is limited by the characteristics of the populations studied, and the evolutionary constraints on human Mendelian variation. To truly empower clinicians and patients, the successful implementation of a genome-first approach to rare cardiovascular disease will require the nuanced incorporation of population-based discovery with detailed investigation of rare disease cohorts and prospective variant evaluation.This publication has 58 references indexed in Scilit:
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular EventsThe New England Journal of Medicine, 2015
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular EventsThe New England Journal of Medicine, 2015
- Cardiac Structural and Sarcomere Genes Associated With Cardiomyopathy Exhibit Marked Intolerance of Genetic VariationCirculation: Cardiovascular Genetics, 2012
- Evolution and Functional Impact of Rare Coding Variation from Deep Sequencing of Human ExomesScience, 2012
- A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathyHeart, 2011
- A map of human genome variation from population-scale sequencingNature, 2010
- DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness modelEuropean Heart Journal, 2010
- Estimation of the Warfarin Dose with Clinical and Pharmacogenetic DataThe New England Journal of Medicine, 2009
- Finishing the euchromatic sequence of the human genomeNature, 2004
- Association of Long QT Syndrome Loci and Cardiac Events Among Patients Treated With β-BlockersJAMA, 2004